← Leaderboards
George Victor Thomas
Oregon Health & Science University
$5,625,841
Attributed
$5,625,841
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,534,882 · 8
By mechanism
U2C$8,029,309 · 2
R01$3,313,450 · 2
P30$1,069,113 · 1
R21$651,400 · 2
P01$471,610 · 1
Top collaborators
- Gordon B. Mills5 shared
- Jeremy Goecks3 shared
- Emek Demir2 shared
- Joe W. Gray2 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsSamplingSignal TransductionTissuesSpecimenCellsParaffin EmbeddingTumorImmunohistochemistryCollectionCancer CellLaboratoriesImageFreezingImmunofluorescence ImmunologicResearch PersonnelProductionStainsBiologicalEnsureMemberClinical TrialsPathway InteractionsResistance
Grant awards (35)
Developing novel polytherapies for Non-Clear Cell Renal Cell Carcinoma$381,047
R01 · FY2025 · CA · contact PI
Developing novel polytherapies for Non-Clear Cell Renal Cell Carcinoma$383,940
R01 · FY2024 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast Cancer$923,254
U2C · FY2023 · CA
Developing novel polytherapies for Non-Clear Cell Renal Cell Carcinoma$137,183
R01 · FY2023 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,747,063
U2C · FY2022 · CA
Developing novel polytherapies for Non-Clear Cell Renal Cell Carcinoma$401,074
R01 · FY2022 · CA · contact PI
Biospecimen Acquisition, Processing and Classification Unit$17,254
U2C · FY2022 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,723,236
U2C · FY2021 · CA
Developing novel polytherapies for Non-Clear Cell Renal Cell Carcinoma$422,042
R01 · FY2021 · CA · contact PI
Biolibrary and Pathology$299,051
P30 · FY2021 · CA · contact PI
Novel Treatment Strategies for Cancer$287,980
R21 · FY2021 · CA · contact PI
Biospecimen Acquisition, Processing and Classification Unit$11,297
U2C · FY2021 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,757,743
U2C · FY2020 · CA
Biolibrary and Pathology$330,741
P30 · FY2020 · CA · contact PI
Biospecimen Acquisition, Processing and Classification Unit$44,709
U2C · FY2020 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,757,745
U2C · FY2019 · CA
Determining how autophagy mediates resistance to cancer therapies$162,450
R21 · FY2019 · CA · contact PI
Biolibrary and Pathology$133,142
P30 · FY2019 · CA · contact PI
Biospecimen Acquisition, Processing and Classification Unit$47,008
U2C · FY2019 · CA · contact PI
Determining how autophagy mediates resistance to cancer therapies$200,970
R21 · FY2018 · CA · contact PI
Biolibrary and Pathology$133,142
P30 · FY2018 · CA · contact PI
Biolibrary and Pathology$16,564
P30 · FY2018 · CA · contact PI
Biolibrary and Pathology$15,000
P30 · FY2018 · CA · contact PI
Biolibrary and Pathology$8,331
P30 · FY2018 · CA · contact PI
Inhibiting VHL-positive kidney cancer$319,550
R01 · FY2017 · CA · contact PI
Biolibrary and Pathology$133,142
P30 · FY2017 · CA · contact PI
HISTOPATHOLOGY CORE$95,772
P01 · FY2017 · HD · contact PI
Inhibiting VHL-positive kidney cancer$319,550
R01 · FY2016 · CA · contact PI
HISTOPATHOLOGY CORE$95,612
P01 · FY2016 · HD · contact PI
Inhibiting VHL-positive kidney cancer$319,550
R01 · FY2015 · CA · contact PI
HISTOPATHOLOGY CORE$91,361
P01 · FY2015 · HD · contact PI
Inhibiting VHL-positive kidney cancer$309,964
R01 · FY2014 · CA · contact PI
HISTOPATHOLOGY CORE$93,091
P01 · FY2014 · HD · contact PI
Inhibiting VHL-positive kidney cancer$319,550
R01 · FY2013 · CA · contact PI
HISTOPATHOLOGY CORE$95,774
P01 · FY2013 · HD · contact PI